metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab
	CheckMate 067 (NI vs I ; all population), 2015 N Engl J Med 2017;377:1345-1356 N. Engl. J. Med. 2019; 381:1535-1546 Lancet Oncol. 2018; 19:1480-1492 N. Engl. J. Med. 2015; 373:23-34 Eur. J. Cancer 2017; 82:80-91 Qual Life Res 2019; 28:109-119 NCT01844505	RCT	mML - L1 - all population	nivolumab plus ipilimumab	ipilimumab	patients with previously untreated, unresectable or metastatic histologically confirmed stage III or IV melanoma.	314 / 315	low	conclusif	demonstrated 45 % decrease in deaths (OS) (PE) demonstrated 58 % decrease in progression or deaths (PFS) (PE) suggested 48 % decrease in deaths (OS) (extension) suggested 58 % decrease in PFS (extension) more...
	CheckMate 069 (all population), 2015 N Engl J Med 2015;372:2006-17 Lancet Oncol. 2016; 17:1558-1568 NCT01927419	RCT	mML - L1 - all population	nivolumab and ipilimumab	ipilimumab	unresectable, previously untreated stage III or IV melanoma with measurable disease, with BRAF Wild-Type Tumors and BRAF mutant	95 / 47	low	conclusif	demonstrated 62 % decrease in progression or deaths (PFS) (PE) suggested 64 % decrease in PFS (extension) demonstrated 14.1-fold increase in objective responses (ORR) (PE)
versus nivolumab alone
	nivolumab plus ipilimumab
	CheckMate 067 (NI vs N) EXPLORATORY, 2015 N Engl J Med 2017;377:1345-1356 N. Engl. J. Med. 2019; 381:1535-1546 Lancet Oncol. 2018; 19:1480-1492 N. Engl. J. Med. 2015; 373:23-34 Eur. J. Cancer 2017; 82:80-91 Qual Life Res 2019; 28:109-119 NCT01844505	RCT	mML - L1 - all population	nivolumab plus ipilimumab	nivolumab	patients with previously untreated, unresectable or metastatic histologically confirmed stage III or IV melanoma.	314 / 316	low	inconclusive	suggested 35 % decrease in deaths (OS) suggested 21 % decrease in PFS (extension) suggested 26 % decrease in progression or deaths (PFS)
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab
	CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 N Engl J Med 2015;372:2006-17 Lancet Oncol. 2016; 17:1558-1568 NCT01927419	RCT	mML - L1 - BRAF mutant	nivolumab and ipilimumab	ipilimumab	unresectable, previously untreated stage III or IV melanoma with measurable disease, with BRAF mutant Tumors	23 / 10	low	inconclusive	no statistically significant result
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab
	CheckMate 069 (BRAF wild type), 2015 N Engl J Med 2015;372:2006-17 Lancet Oncol. 2016; 17:1558-1568 NCT01927419	RCT	mML - L1 - BRAF wild	nivolumab and ipilimumab	ipilimumab	unresectable, previously untreated stage III or IV melanoma with measurable disease, with BRAF Wild-Type Tumors	72 / 37	low	conclusif	demonstrated 60 % decrease in progression or deaths (PFS) (PE) demonstrated 12.0-fold increase in objective responses (ORR) (PE)

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild